BeyondSpring Inc Stock News

Rothschild Investment Corp IL bought a new stake in BeyondSpring Inc. (NASDAQ:BYSI) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 12,500 shares of the companys stock, valued at approximately $197,000. Several other institutional investors have also recently bought and []

BeyondSpring Inc. (NASDAQ:BYSI) price on Friday, November 19, fall -0.53% below its previous days close as a downside momentum from buyers pushed the stocks value to $13.25. A look at the stocks price movement, the close in the last trading session was $13.32, moving within a range at $13.03 and $13.77. The beta value (5-Year BeyondSpring Inc. (BYSI) Outlook: Looking Back For Insights Read More »

Geode Capital Management LLC increased its position in BeyondSpring Inc. (NASDAQ:BYSI) by 14.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 198,094 shares of the companys stock after buying an additional 25,741 shares during the quarter. Geode Capital Management LLC owned 0.51% []

Related Stocks: BYSI , NXE , AMRS , CG , MO , CCJ ,

Today, we look back in on a small oncology company called BeyondSpring for the first time since early this year. The stock quadrupled in August on good trial results but has fallen back 40% since then

JPMorgan Chase & Co. decreased its stake in BeyondSpring Inc. (NASDAQ:BYSI) by 65.6% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,141 shares of the company’s stock after selling 36,513 shares during the quarter. JPMorgan Chase & Co.’s holdings […]

JPMorgan Chase & Co. lowered its holdings in BeyondSpring Inc. (NASDAQ:BYSI) by 65.6% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 19,141 shares of the company’s stock after selling 36,513 shares during the quarter. JPMorgan Chase & Co.’s holdings in BeyondSpring […]

These drugmakers have big events that should occur before the end of 2021.

BeyondSpring Pharmaceuticals Inc (NASDAQ: BYSI) shared the final intention-to-treat (ITT) dataset from its DUBLIN-3 Phase 3 trial of plinabulin. The trial evaluated plinabulin combined with docetax

Shares of BeyondSpring Inc (NASDAQ: BYSI) gained more than 200% in August as the pharmaceutical company said its candidate drug (Plinabulin) improved life expectancy for patients with advanced lung ca

NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Pharmaceuticals (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer

BeyondSpring Pharmaceuticals has the potential to address the billion-dollar anti-cancer markets on top of a large unmet medical need to reduce chemo-induced neutropenia (CIN) with revenues beginning

BeyondSpring Pharmaceuticals (NASDAQ: BYSI) announced new plinabulin data from its chemotherapy-induced neutropenia (CIN) prevention program at the European Society for Medical Oncology (ESMO21) 20

Plinabulin in combination with G-CSF is undergoing regulatory review for potential approval in the U.S. and China for the prevention of CIN, with a U.S. PDUFA date of November 30, 2021. Plinabulin in

BeyondSpring(NASDAQ:BYSI) stock fell by 4.13% on Monday after the company reported their Q2 earnings results on Friday, September 10, 2021 at 07:00 AM. Here's what investors need to know about the ann